Logo image of SRGA

SURGALIGN HOLDINGS INC (SRGA) Stock Fundamental Analysis

NASDAQ:SRGA - Nasdaq - US86882C2044 - Common Stock - Currency: USD

0.1829  -0.09 (-32.98%)

After market: 0.1235 -0.06 (-32.48%)

Fundamental Rating

1

Overall SRGA gets a fundamental rating of 1 out of 10. We evaluated SRGA against 188 industry peers in the Health Care Equipment & Supplies industry. SRGA has a bad profitability rating. Also its financial health evaluation is rather negative. SRGA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SRGA has reported negative net income.
SRGA had a negative operating cash flow in the past year.
SRGA had negative earnings in each of the past 5 years.
In the past 5 years SRGA reported 4 times negative operating cash flow.
SRGA Yearly Net Income VS EBIT VS OCF VS FCFSRGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

The profitability ratios for SRGA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRGA Yearly ROA, ROE, ROICSRGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

SRGA has a Gross Margin of 47.06%. This is comparable to the rest of the industry: SRGA outperforms 43.00% of its industry peers.
SRGA's Gross Margin has been stable in the last couple of years.
SRGA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
SRGA Yearly Profit, Operating, Gross MarginsSRGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

SRGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRGA has more shares outstanding
Compared to 1 year ago, SRGA has a worse debt to assets ratio.
SRGA Yearly Shares OutstandingSRGA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
SRGA Yearly Total Debt VS Total AssetsSRGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

SRGA has an Altman-Z score of -14.39. This is a bad value and indicates that SRGA is not financially healthy and even has some risk of bankruptcy.
SRGA has a Altman-Z score of -14.39. This is amonst the worse of the industry: SRGA underperforms 85.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.39
ROIC/WACCN/A
WACC5.62%
SRGA Yearly LT Debt VS Equity VS FCFSRGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.67 indicates that SRGA has no problem at all paying its short term obligations.
With a Current ratio value of 2.67, SRGA is not doing good in the industry: 60.87% of the companies in the same industry are doing better.
SRGA has a Quick Ratio of 2.00. This is a normal value and indicates that SRGA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.00, SRGA is in line with its industry, outperforming 42.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2
SRGA Yearly Current Assets VS Current LiabilitesSRGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

SRGA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.34%, which is quite impressive.
The Revenue for SRGA has decreased by -11.04% in the past year. This is quite bad
Measured over the past years, SRGA shows a very negative growth in Revenue. The Revenue has been decreasing by -21.76% on average per year.
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%

3.2 Future

SRGA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -26.80% yearly.
SRGA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.28% yearly.
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SRGA Yearly Revenue VS EstimatesSRGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SRGA Yearly EPS VS EstimatesSRGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SRGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SRGA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRGA Price Earnings VS Forward Price EarningsSRGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRGA Per share dataSRGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

SRGA's earnings are expected to decrease with -26.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SRGA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGALIGN HOLDINGS INC

NASDAQ:SRGA (6/30/2023, 8:00:01 PM)

After market: 0.1235 -0.06 (-32.48%)

0.1829

-0.09 (-32.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-11 2023-05-11/amc
Earnings (Next)08-07 2023-08-07/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners110.88%
Ins Owner Change0%
Market Cap1.68M
Analysts82
Price Target2.3 (1157.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.19%
Min EPS beat(2)34.2%
Max EPS beat(2)62.17%
EPS beat(4)4
Avg EPS beat(4)31.3%
Min EPS beat(4)12.05%
Max EPS beat(4)62.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)6.19%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)15.74%
Revenue beat(4)1
Avg Revenue beat(4)0.19%
Min Revenue beat(4)-7.31%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.18%
EPS NQ rev (1m)-0.98%
EPS NQ rev (3m)36.11%
EPS NY rev (1m)-0.98%
EPS NY rev (3m)-47.17%
Revenue NQ rev (1m)0.98%
Revenue NQ rev (3m)-16.92%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)-37.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.81
EYN/A
EPS(NY)-11.27
Fwd EYN/A
FCF(TTM)-5.36
FCFYN/A
OCF(TTM)-4.57
OCFYN/A
SpS8.51
BVpS-0.97
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.06%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.98%
GM growth 5Y-0.73%
F-Score2
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 341.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2
Altman-Z -14.39
F-Score2
WACC5.62%
ROIC/WACCN/A
Cap/Depr(3y)371.14%
Cap/Depr(5y)257.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y-58.25%
EPS Next 2Y-26.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.04%
Revenue growth 3Y-11.28%
Revenue growth 5Y-21.76%
Sales Q2Q%-18.72%
Revenue Next Year-37.13%
Revenue Next 2Y-17.44%
Revenue Next 3Y10.86%
Revenue Next 5Y5.28%
EBIT growth 1Y-18.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.51%
OCF growth 3YN/A
OCF growth 5YN/A